Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human study of LMT503 in healthy volunteers
NL-OMON51292Phase 1Not yet recruiting
- Sponsor
- Lmito Therapeutics
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LMT503 in inflammatory bowel disease (IBD) (9 arms), sponsored by Lmito Therapeutics. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
LMT503
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON51292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51292.